BOSTON, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools"), today announced the completion of
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced it has entered into a definitive agreement to sell its
BOSTON, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
NEW YORK, Sept. 10, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
NEW YORK, Sept. 8, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the quarter ended June 30, 2026.
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
NEW YORK, July 20, 2026 /PRNewswire/ --Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged
